LI
VRDN icon

LRI Investments’s Viridian Therapeutics VRDN Stock Holding History

LRI Investments’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$845 Buy
+46
New +$741 ﹤0.01% 1413

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

LRI Investments's VRDN Position: Q2 2026 in Review

LRI Investments opened a new position in Viridian Therapeutics (VRDN) in Q2 2026: 46 shares worth $845. The stake represents ﹤0.01% of the portfolio and ranks #1413 among its holdings.

214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • LRI Investments held 46 shares of Viridian Therapeutics worth $845 as of Q2 2026.
  • Viridian Therapeutics was a new LRI Investments position in Q2 2026.
  • Viridian Therapeutics made up ﹤0.01% of LRI Investments's portfolio in Q2 2026, its #1413 holding.
  • 214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on LRI Investments's 13F filing for Q2 2026, filed 14 Jul 2026.